Original article
Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score1

https://doi.org/10.1016/j.soard.2018.01.027Get rights and content

Abstract

Background

Metabolic surgery has become increasingly accepted for the treatment of type 2 diabetes (T2D). However, there is limited evidence regarding the optimal candidate and surgical procedure. Although a new individualized metabolic surgery (IMS) score was recently proposed for procedure selection, it has yet to be validated.

Objective

To validate the IMS score with regard to remission of T2D after metabolic surgery and compare it with the age, body mass index, C-peptide level, and duration of T2D (ABCD) score.

Setting

Hospital-based bariatric center.

Methods

A total of 310 T2D patients who underwent gastric bypass and sleeve gastrectomy at an academic center in Taiwan and had a minimum 5-year follow-up (2004–2012) were examined for the predictive power of complete remission using the IMS and the ABCD scoring systems.

Results

At the 5-year follow-up, weight loss was 27.5%, with mean body mass index decreasing from 37.8 to 27.9 kg/m2, mean glycated hemoglobin decreased from 8.6% to 6.1%, and prolonged remission of T2D achieved in 224 (72.3%) T2D patients. Remission rates were higher in patients who underwent gastric bypass than in those who underwent sleeve gastrectomy (73.6% versus 66.1%; P = .04), regardless of T2D severity, and were 96%, 68%, and 16% in patients with IMS mild, moderate, and severe scores, respectively. Although both scores predicted the success of surgery, the ABCD was better in patients with IMS moderate scores.

Conclusion

Metabolic surgery is an option for T2D patients with obesity. The ABCD score may be better at predicting T2D remission after metabolic surgery compared with the IMS score.

Section snippets

Methods

The institutional review board approved this retrospective study. We identified patients who were enrolled in a metabolic surgery program for T2D treatment at Min-Sheng General Hospital Metabolic Surgery Institute between 2004 and 2012. During this period, 670 patients with T2D underwent metabolic surgery. Patients with complete baseline and postoperative follow-up of at least 5 years were included. Patients who had revision surgery and those who were lost to follow-up were excluded. Notably,

Patient characteristics and change after surgery

The data set included 310 patients who underwent either GB (RYGB in 125 patients and SAGB in 120) or SG with a complete follow-up of at least 5 years. Baseline characteristics of the study cohorts are summarized in Table 2. Patients had a mean BMI of 37.8 ± 7.6 kg/m2 (range, 24.1–59.0), a median duration of T2D of 3.6 ± 4.4 years (range, .1–26), and HbA1C of 8.6 ± 1.8% (range, 5.6–13.2). Average number of diabetes medications at baseline was 1.2 ± .9, with 42 (16%) patients receiving insulin

Discussion

In this report, we validated the usefulness of the IMS score in predicting the probability of T2D remission after metabolic surgery. To the best of our knowledge, our study is the first to validate the IMS score in a different ethnic cohort (Asian). The probability of long-term T2D remission was 96%, 68%, and 16% for patients with IMS scores of mild, moderate, and severe, respectively. Thus, T2D patients may be selected for metabolic surgery according to their IMS scores. However, this study

Conclusions

Metabolic surgery is a well-known and promising treatment indicated for insufficiently controlled T2D in patients with obesity. The ABCD scoring system may be better at predicting metabolic responses after bariatric surgery in patients with moderate T2D.

Disclosures

The authors have no commercial associations that might be a conflict of interest in relation to this article.

References (42)

  • M. Lakdawala et al.

    Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30-35 kg/m(2)) Indian patients with type 2 diabetes mellitus

    Surg Obes Relat Dis

    (2013)
  • P. Zimmer et al.

    Global and societal implications of the diabetes epidemic

    Nature

    (2001)
  • H.C. Gerstein et al.

    Effects of intensive glucose lowering in type 2 diabetes

    N Engl J Med

    (2008)
  • P.R. Schauer et al.

    Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes

    N Engl J Med

    (2017)
  • S. Ikramuddin et al.

    Durability of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild-to-moderate obesity: a randomized control trial

    Diabetes Care

    (2016)
  • D. Cummings et al.

    Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomized controlled trial

    Diabetologia

    (2016)
  • J.B. Dixon et al.

    Bariatric surgery: an IDF statement for obese type 2 diabetes

    Diabet Med

    (2011)
  • W. Cefalu et al.

    Metabolic surgery for type 2 diabetes: changing the landscape of diabetes care

    Diabetes Care

    (2016)
  • L. Sjostrom et al.

    Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

    N Engl J Med

    (2004)
  • M.T. Hayes et al.

    A model for predicting the resolution of type 2 diabetes in severely obese subjects following Roux-en Y gastric bypass surgery

    Obes Surg

    (2011)
  • A.M. Ramos- Levi et al.

    Statistical models to predict type 2 diabetes remission after bariatric surgery

    J Diabetes

    (2014)

    • Cited by (39)

    • Validation of the individualized metabolic surgery score for bariatric procedure selection in the merged data of two randomized clinical trials (SLEEVEPASS and SM-BOSS)

      2023, Surgery for Obesity and Related Diseases
      Citation Excerpt :

      Many scoring systems have been developed to predict T2D remission after bariatric surgery such as DiaRem [22], advanced-DiaRem (ad-DiaRem) [24], DiaBetter [25] and ABCD scores [20]. Chen et al. [28] reported that the ABCD scores have better discriminative ability between the procedures compared with the IMS score. This was suggested to derive from the lack of C-peptide value in the IMS score as it has been shown to predict T2D remissions [36–38].

    • Predictors of diabetes relapse after metabolic surgery in Asia

      2022, Surgery for Obesity and Related Diseases
      Citation Excerpt :

      Most of the reported models were developed in Western countries and composed of 2–6 variables, including age, BMI, and associated markers of diabetic severity, reflecting the reserved function of pancreatic ß-cells. Although most of the models had good discrimination powers, Western-developed scores seem to have better predictive effects in Western countries [7,13], while the ABCD score had better predictive effects in Asia [14,15], noted in several comparison studies. The current study revealed similar AUCs between the ABCD and DiaRem2 scores for predicting 1- or 3-year remission of T2D, but the shape of the receiver operating characteristic curve was smoother in the ABCD score than that in the DiaRem2 score either for predicting 1-year or 3-year remission (Fig. 1).

    • Reply for comments on “Roux-en-Y and One-anastomosis Gastric Bypass Surgery Are Superior to Sleeve Gastrectomy in Lowering Glucose and Cholesterol Levels Independent of Weight Loss: a Propensity-Score Weighting Analysis”

      2024, Obesity Surgery

    • Comparison of various prediction models in the effect of laparoscopic sleeve gastrectomy on type 2 diabetes mellitus in the Chinese population 5 years after surgery

      2024, Chinese Medical Journal

    • How Good is Stratification and Prediction Model Analysis Between Primary and Revisional Roux-en-Y Gastric Bypass Surgery? A Multi-center Study and Narrative Review

      2023, Obesity Surgery

    • M-INDEX AS A PREDICTOR OF GLYCEMIA NORMALIZATION IN T2D PATIENTS EARLY AFTER BARIATRIC SURGERY

      2023, Diabetes Mellitus
    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    View full text
    © 2018 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.